Treffer 1 - 6 von 6 für Suche 'Murase, Tosei', Suchdauer: 3,17s Treffer weiter einschränken
  1. 1
    Immunopathogenesis of Experimental Ulcerative Colitis Is Mediated by Eosinophil Peroxidase

    Immunopathogenesis of Experimental Ulcerative Colitis Is Mediated by Eosinophil Peroxidase von Forbes, Elizabeth, Murase, Tosei, Yang, Ming, Matthaei, Klaus I, Lee, James J, Lee, Nancy A, Foster, Paul S, Hogan, Simon P


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    Construction of a T cell receptor signaling range for spontaneous development of autoimmune disease

    Construction of a T cell receptor signaling range for spontaneous development of autoimmune disease von Tanaka, Atsushi, Maeda, Shinji, Nomura, Takashi, Llamas-Covarrubias, Mara Anais, Tanaka, Satoshi, Jin, Lin, Lim, Ee Lyn, Morikawa, Hiromasa, Kitagawa, Yohko, Akizuki, Shuji, Ito, Yoshinaga, Fujimori, Chihiro, Hirota, Keiji, Murase, Tosei, Hashimoto, Motomu, Higo, Junichi, Zamoyska, Rose, Ueda, Ryuzo, Standley, Daron M, Sakaguchi, Noriko, Sakaguchi, Shimon


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers

    Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunt... von Murase, Tosei, Takizawa, Masaomi, Galitz, Lawrence, Flach, Stephen, Murray, Valene, Gufford, Brandon, Suwa, Akira


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  4. 4
    P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC

    P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC von Kelly, Ronan, Horn, Leora, Chih-Hsin Yang, James, Lee, Dae Ho, Desai, Bhardwaj, Fleege, Tanya, Jie, Fei, Poondru, Srinivasu, Keating, Anne, Whitcomb, Debbie, Murase, Tosei, Uegaki, Koichi, Aoyama, Kouji, Nakagawa, Kazuhiko

    Veröffentlicht in Journal of thoracic oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  5. 5
    P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC: Topic: Phase III

    P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC: Topic: Phase III von Kelly, Ronan, Horn, Leora, Chih-Hsin Yang, James, Lee, Dae Ho, Desai, Bhardwaj, Fleege, Tanya, Jie, Fei, Poondru, Srinivasu, Keating, Anne, Whitcomb, Debbie, Murase, Tosei, Uegaki, Koichi, Aoyama, Kouji, Nakagawa, Kazuhiko

    Veröffentlicht in Journal of thoracic oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  6. 6
    P-2-137 SOLAR : Comparing efficacy and safety of ASP 8273 with erlotinib or gefitinib as first-line treatment in subjects with EGFR mutation-positive NSCLC

    P-2-137 SOLAR : Comparing efficacy and safety of ASP 8273 with erlotinib or gefitinib as first-line treatment in subjects with EGFR mutation-positive NSCLC von Ronan Kelly, Leora Horn, Chih-Hsin Yang, Dae Ho Lee, Bhardwaj Desai, Tanya Fleege, Fei Jie, Srinivasu Poondru, Anne Keating, Debbie Whitcomb, Tosei Murase, Koichi Uegaki, Kouji Aoyama, Kazuhiko Nakagawa

    Veröffentlicht in Japanese Journal of Lung Cancer

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: